MiMedx® Ranked in Georgia's Top 100 Public Companies
MARIETTA, Ga., Sept. 18, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has been selected to Georgia's 2013 Top 100 Public Companies. This prestigious list is sponsored by GeorgiaTrend Magazine and determined by S&P Capital IQ, a part of McGraw Hill Financial. The 2013 list is based on fiscal year 2012 financial results.
The 2013 publication marks the first year that MiMedx has reached Georgia's Top 100 Public Companies list. MiMedx is one of two Georgia-based public healthcare companies to join the Top 100 in 2013.
Parker H. Petit, Chairman and CEO, said, "We are pleased with our inaugural inclusion in the 2013 Top 100 Public Companies in Georgia. We are flattered that the GeorgiaTrend article unveiling the 2013 list recognized MiMedx for our recent accomplishments, including adding over 100 new jobs in the Atlanta area, developing our new headquarters facility, doubling our manufacturing capacity and tripling our 2012 sales over 2011. As more results from our clinical studies chronicling the clinical and cost effectiveness of our PURION® processed dehydrated human amnion/chorion membrane allografts (dHACM) are published, we expect the demand for our tissue allografts to continue to increase."
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx® is the leading supplier of amniotic tissue, having supplied over 170,000 allografts to date to distributors and OEMs for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to the results of in-process and future clinical studies and the expected impact on demand for the Company's tissue allografts. These statements are based on current information and belief, and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the results of the clinical studies do not support the clinical and cost-effectiveness of the Company's tissue allografts or do not increase demand for the Company's tissue allografts, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2012 and the Company's most recent Form 10-Q. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.
SOURCE MiMedx Group, Inc.